Caplin Point Laboratories Limited – SWOT Analysis

Strengths Strong Presence in Latin America – Established pharmaceutical business in Latin American markets provides strong export diversification. Integrated Pharma Operations – Presence across APIs, formulations, injectables, and branded generics improves operational efficiency. USFDA and Global Regulatory Approvals – Multiple approved facilities strengthen export credibility and entry into regulated markets. Weaknesses Geographic Concentration Risk – Heavy dependence on Latin American markets increases regional business risk. Regulatory Compliance Exposure – Pharma operations remain vulnerable to inspections and compliance issues. Limited Domestic Market Presence – Lower India-focused business compared to larger pharma peers. Opportunities US Market Expansion – Growing presence in the US injectables and specialty products segment supports future growth. China+1 Opportunity – Global sourcing diversification benefits Indian pharma exporters. New Product Launches – Injectable and complex generic launches can improve revenue and margins. Threats USFDA Regulatory Action – Warning letters or compliance issues can impact exports significantly. Pricing Pressure in Generics – Competition in export markets may reduce margins. Currency Volatility – Forex fluctuations affect export realization and profitability. Raw Material Dependency – API sourcing disruptions or cost increases may pressure operations. Competition from Global Generic Players – Large international pharma companies create pricing pressure. Disclaimer AASHISH SEBI RA INH000013174 This analysis is only for educational and informational purposes and should not be considered as buy/sell recommendation. Investors should consult their financial advisor before making any investment decision. Stock market investments are subject to market risks. Past performance does not guarantee future results.